These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26325204)

  • 1. Serum Level of Soluble Receptor for Advanced Glycation End Products Is Associated with A Disintegrin And Metalloproteinase 10 in Type 1 Diabetes.
    Lee AC; Lam JK; Shiu SW; Wong Y; Betteridge DJ; Tan KC
    PLoS One; 2015; 10(9):e0137330. PubMed ID: 26325204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
    Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
    Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10).
    Raucci A; Cugusi S; Antonelli A; Barabino SM; Monti L; Bierhaus A; Reiss K; Saftig P; Bianchi ME
    FASEB J; 2008 Oct; 22(10):3716-27. PubMed ID: 18603587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGCG-rich green tea extract stimulates sRAGE secretion to inhibit S100A12-RAGE axis through ADAM10-mediated ectodomain shedding of extracellular RAGE in type 2 diabetes.
    Huang SM; Chang YH; Chao YC; Lin JA; Wu CH; Lai CY; Chan KC; Tseng ST; Yen GC
    Mol Nutr Food Res; 2013 Dec; 57(12):2264-8. PubMed ID: 23901023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.
    Prasad K; Dhar I; Zhou Q; Elmoselhi H; Shoker M; Shoker A
    Mol Cell Biochem; 2016 Dec; 423(1-2):105-114. PubMed ID: 27714575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated endogenous secretory receptor for advanced glycation end products (esRAGE) levels are associated with circulating soluble RAGE levels in diabetic children.
    Saito R; Araki S; Yamamoto Y; Kusuhara K
    J Pediatr Endocrinol Metab; 2017 Jan; 30(1):63-69. PubMed ID: 27941172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases.
    Zhang L; Bukulin M; Kojro E; Roth A; Metz VV; Fahrenholz F; Nawroth PP; Bierhaus A; Postina R
    J Biol Chem; 2008 Dec; 283(51):35507-16. PubMed ID: 18952609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered expression of a disintegrin and metalloproteinase 10 in peripheral blood mononuclear cells in type 2 diabetes mellitus patients with the acute coronary syndrome: a pilot study.
    Ragavi R; Adole PS; Vinod KV; Pillai AA
    Endocrine; 2022 Sep; 77(3):461-468. PubMed ID: 35877008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADAM10 modulates calcitriol-regulated RAGE in cardiomyocytes.
    Lee TW; Kao YH; Lee TI; Chen YJ
    Eur J Clin Invest; 2017 Sep; 47(9):675-683. PubMed ID: 28722189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.
    Tam XH; Shiu SW; Leng L; Bucala R; Betteridge DJ; Tan KC
    Clin Sci (Lond); 2011 Jan; 120(2):81-9. PubMed ID: 20726839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic studies on receptor for advanced glycation end product variants in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease.
    Ohlmeier S; Mazur W; Salmenkivi K; Myllärniemi M; Bergmann U; Kinnula VL
    Proteomics Clin Appl; 2010 Jan; 4(1):97-105. PubMed ID: 21137019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of soluble receptor for advanced glycation end products isoforms and advanced glycation end products in long-living individuals.
    Scavello F; Tedesco CC; Castiglione S; Maciag A; Sangalli E; Veglia F; Spinetti G; Puca AA; Raucci A
    Biomark Med; 2021 Aug; 15(11):785-796. PubMed ID: 34236256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic dysfunction in Emirati subjects in Abu Dhabi: Relationship to levels of soluble RAGEs.
    Abdulle A; Inman CK; Saleh A; Noshi M; Galani D; Abdelwareth L; Alsafar H; Elfatih A; Al Shamsi H; Ali R; Li H; Ramasamy R; Schmidt AM; Benbarka MM; Hassan MH
    J Clin Transl Endocrinol; 2019 Jun; 16():100192. PubMed ID: 31080742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of the plasma levels of soluble RAGE and endogenous secretory RAGE with oxidative stress in pre-diabetic patients.
    Huang M; Que Y; Shen X
    J Diabetes Complications; 2015 Apr; 29(3):422-6. PubMed ID: 25659638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cleaved but not endogenous secretory RAGE is associated with outcome in acute ischemic stroke.
    Tang SC; Yeh SJ; Tsai LK; Hu CJ; Lien LM; Peng GS; Yang WS; Chiou HY; Jeng JS
    Neurology; 2016 Jan; 86(3):270-6. PubMed ID: 26683643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes.
    Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Umayahara Y; Kosugi K; Yamasaki Y
    Atherosclerosis; 2009 May; 204(1):288-92. PubMed ID: 18926539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of chronic hypoxia on RAGE and its soluble forms in lungs and plasma of mice.
    Gopal P; Gosker HR; Theije CC; Eurlings IM; Sell DR; Monnier VM; Reynaert NL
    Biochim Biophys Acta; 2015 May; 1852(5):992-1000. PubMed ID: 25703138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single high-fat meal alters human soluble RAGE profiles and PBMC RAGE expression with no effect of prior aerobic exercise.
    Fuller KNZ; Valentine RJ; Miranda ER; Kumar P; Prabhakar BS; Haus JM
    Physiol Rep; 2018 Jul; 6(14):e13811. PubMed ID: 30047241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JNK and ATF4 as two important platforms for tumor necrosis factor-α-stimulated shedding of receptor for advanced glycation end products.
    Miyoshi A; Koyama S; Sasagawa-Monden M; Kadoya M; Konishi K; Shoji T; Inaba M; Yamamoto Y; Koyama H
    FASEB J; 2019 Mar; 33(3):3575-3589. PubMed ID: 30452882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.
    Gohda T; Tanimoto M; Moon JY; Gotoh H; Aoki T; Matsumoto M; Shibata T; Ohsawa I; Funabiki K; Tomino Y
    Diabetes Res Clin Pract; 2008 Aug; 81(2):196-201. PubMed ID: 18550199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.